Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Eli Lilly Commits $3 Billion to China Manufacturing – Orforglipron Production Capacity and Local Supply Chain Expansion

Fineline Cube Mar 12, 2026
Deals Drug

Huadong Medicine’s HDM2024 Wins FDA Phase I Approval – First-in-Class EGFR/HER3 Bispecific ADC Targets Advanced Solid Tumors

Fineline Cube Mar 12, 2026
Company Deals

Eli Lilly Partners with WHO Foundation on Global Obesity Health Systems – $1.68 Million Commitment Through 2029

Fineline Cube Mar 11, 2026
Company Deals Drug

AstraZeneca Initiates CLARITY-Gastric 02 Phase III – Sonesitatug Vedotin Combo Triggers $45 Million Milestone from KYM Biosciences

Fineline Cube Mar 11, 2026
Company Deals

GSK Licenses Linerixibat to Alfasigma for $300 Million Upfront – IBAT Inhibitor Targets PBC Pruritus with $690 Million Total Deal Value

Fineline Cube Mar 10, 2026
Policy / Regulatory

FDA Streamlines Biosimilar Development – New Guidance Cuts PK Study Costs by 50%, Accelerates Path to Market

Fineline Cube Mar 10, 2026
Company Drug

Huadong Medicine’s HDM2017 Wins FDA Orphan Drug Designation – CDH17 ADC Targets Three Gastrointestinal Cancers

Fineline Cube Mar 12, 2026
Company Drug

Hengrui’s SHR-2524 Wins NMPA Phase I Approval – Novel Subcutaneous Formulation Plus Bevacizumab Targets First-Line Liver Cancer

Fineline Cube Mar 12, 2026
Company Medical Device

Inari Medical Wins NMPA Approval for Thrombectomy Stent System in China

Fineline Cube Mar 17, 2025

US-based Inari Medical, Inc. (NASDAQ: NARI), set to be acquired by Stryker (NYSE: SYK), announced...

Company Drug

Jiangsu Hengrui Pharmaceuticals’ Tegileridine Approved for Postoperative Pain Management

Fineline Cube Mar 17, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced receiving another indication approval from the...

Company Drug

Doma Biopharmaceutical’s HER3-MUC1 Targeted ADC DM002 Receives NMPA Clinical Approval

Fineline Cube Mar 17, 2025

China-based Doma Biopharmaceutical (Suzhou) Co., Ltd announced receiving clinical approval from the National Medical Products...

Company Medical Device

MicroPort Endovascular MedTech’s Cratos System Approved for Aortic Dissection Treatment

Fineline Cube Mar 17, 2025

Shanghai MicroPort Endovascular MedTech Co., Ltd’s (SHA: 688016) Cratos branched aortic stent graft system has...

Company Drug

Akeso Biopharma’s Penpulimab Approved for First-Line NPC Treatment

Fineline Cube Mar 17, 2025

China-based Akeso Biopharma (HKG: 9926) announced receiving another indication approval from the National Medical Products...

Company Drug

Innovent Biologics’ Sycume Approved by China’s NMPA for Thyroid Eye Disease

Fineline Cube Mar 17, 2025

China-based Innovent Biologics Inc. (HKG: 1801) announced that its New Drug Application (NDA) for Sycume...

Company Drug

Simcere Pharmaceutical’s ADC189 NDA Accepted for Influenza Treatment

Fineline Cube Mar 17, 2025

Simcere Pharmaceutical Group Limited (HKG: 2096) and AnDiConBio announced that the New Drug Application (NDA)...

Company

Rona Therapeutics Secures $25M Pre-B Round to Advance siRNA Therapies

Fineline Cube Mar 16, 2025

Shanghai-based Rona Therapeutics announced the successful completion of a $25 million (RMB 180 million) Pre-B...

Company

Tonghua Golden-Horse Pharmaceutical Embraces AI with DeepSeek R1 for Drug Innovation

Fineline Cube Mar 16, 2025

Tonghua Golden-Horse Pharmaceutical Industry Co., Ltd. (SHE: 000766) recently held a special meeting to deploy...

Digital

DeepSeek’s Rise in the Pharmaceutical Industry: A New Era of AI-Driven Transformation

Fineline Cube Mar 15, 2025

The emergence of DeepSeek-R1 during the Lunar New Year celebrations marked a pivotal moment in...

Company Deals

Pharmavan and Kefeng Changjian Sign Pact to Accelerate SPT-07A Development

Fineline Cube Mar 15, 2025

Suzhou Pharmavan Co., Ltd. has announced plans to enter into a cooperation agreement with Sichuan...

Company Drug

Roche’s Itovebi Approved in China for PIK3CA-Mutated Breast Cancer

Fineline Cube Mar 14, 2025

Itovebi (inavolisib), a best-in-class PI3Kα inhibitor from Swiss giant Roche (SWX: ROG, OTCMKTS: RHHBY), has...

Company Deals

Quantum Hi-Tech and ECNU Establish AI-Driven Drug Manufacturing Lab

Fineline Cube Mar 14, 2025

CRO+CDMO Quantum Hi-Tech (China) Biotechnology Co., Ltd (ChemPartner, SHE: 300149) announced plans to establish an...

Company Deals

BioCity and MSD Enter Clinical Collaboration for BC3195 and Keytruda Combination Trial

Fineline Cube Mar 14, 2025

China-based BioCity Biopharmaceutics Co., Ltd. announced a clinical collaboration agreement with US-based giant Merck, Sharp...

Company Deals Hospital

Shanghai Fosun Pharmaceutical Transfers Unicorn II Holdings Stake to Warburg Pincus Subsidiary

Fineline Cube Mar 14, 2025

China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced plans to transfer...

Company Deals

Salipro Biotech and Boehringer Ingelheim Collaborate on Drug Development for Membrane Proteins

Fineline Cube Mar 14, 2025

Sweden-based Salipro Biotech AB announced a research and license agreement with German pharmaceutical giant Boehringer...

Company Drug

CSPC Pharmaceutical Group Receives FDA Approval for SYH2051 Clinical Trial

Fineline Cube Mar 14, 2025

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) announced receiving approval from the US Food and...

Company Medical Device

Gaush Meditech’s ANTERION Ophthalmic Detector Receives NMPA Market Approval

Fineline Cube Mar 14, 2025

Suzhou-based Gaush Meditech Ltd (HKG: 2407) announced receiving market approval from the National Medical Products...

Company Drug

Bio-Thera Solutions’ BAT2506 Biosimilar Accepted for Review by China’s NMPA

Fineline Cube Mar 14, 2025

China-based Bio-Thera Solutions Inc. (SHA: 688177) announced that a market filing for its BAT2506, a...

Company Drug

Otsuka and Lundbeck Win EU Approval for Rxulti in Adolescent Schizophrenia

Fineline Cube Mar 14, 2025

Japan-based Otsuka Pharmaceutical Co., Ltd and its Danish partner Lundbeck A/S (OTCMKTS: HLUBF) jointly announced...

Posts pagination

1 … 163 164 165 … 633

Recent updates

  • Eli Lilly Commits $3 Billion to China Manufacturing – Orforglipron Production Capacity and Local Supply Chain Expansion
  • Huadong Medicine’s HDM2017 Wins FDA Orphan Drug Designation – CDH17 ADC Targets Three Gastrointestinal Cancers
  • Hengrui’s SHR-2524 Wins NMPA Phase I Approval – Novel Subcutaneous Formulation Plus Bevacizumab Targets First-Line Liver Cancer
  • Boehringer Ingelheim’s Jascayd (Nerandomilast) Launches in Shanghai – First PDE4B Inhibitor for Idiopathic Pulmonary Fibrosis
  • Huadong Medicine’s HDM2024 Wins FDA Phase I Approval – First-in-Class EGFR/HER3 Bispecific ADC Targets Advanced Solid Tumors
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Eli Lilly Commits $3 Billion to China Manufacturing – Orforglipron Production Capacity and Local Supply Chain Expansion

Company Drug

Huadong Medicine’s HDM2017 Wins FDA Orphan Drug Designation – CDH17 ADC Targets Three Gastrointestinal Cancers

Company Drug

Hengrui’s SHR-2524 Wins NMPA Phase I Approval – Novel Subcutaneous Formulation Plus Bevacizumab Targets First-Line Liver Cancer

Company Drug

Boehringer Ingelheim’s Jascayd (Nerandomilast) Launches in Shanghai – First PDE4B Inhibitor for Idiopathic Pulmonary Fibrosis

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.